Orotic Acid

Orotic Acid

SCHEMBL2228871

C=C(N)c1nc[nH]c1N.O=C(O)c1cc(=O)[nH]c(=O)[nH]1.O=C(O)c1cc(=O)[nH]c(=O)[nH]1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
TSHR P16473 2/20 0.41
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 2/20 0.38
DAO P14920 2/20 0.35
GPR84 Q9NQS5 4/20 0.33
NGFR P08138 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
BLM P54132 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.31
ABL1 P00519 1/20 0.30
RIN1 Q13671 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Orotic Acid SCHEMBL867980 1.00 ALDH1A1 (0.54) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL7926736 0.99 ALDH1A1 (0.53) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL7926776 0.99 ALDH1A1 (0.53) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL2228874 0.90 ALDH1A1 (0.57) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL867981 0.90 ALDH1A1 (0.57) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL7929837 0.88 ALDH1A1 (0.55) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL7926780 0.88 ALDH1A1 (0.55) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL2230346 0.76 GDA (0.59) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL1650271 0.75 GDA (0.58) ALDH1A1LMNATSHRCYP1A2CYP2C19
Orotic Acid SCHEMBL2269064 0.75 ALDH1A1 (0.88) ALDH1A1LMNATSHRCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1178796-B1 ORAZAMIDE OROTATE FOR THE PREVENTION OF LIVER DAMAGE TACTICAL THERAPEUTICS INC (US) 2011-07-13 EP claimed
CN-102503825-A Preparation method of medicine intermediate butanone diacid diester compound SHANGHAI HUAYI GROUP CO 2012-06-20 CN disclosed
EP-1178796-B1 ORAZAMIDE OROTATE FOR THE PREVENTION OF LIVER DAMAGE TACTICAL THERAPEUTICS INC (US) 2011-07-13 EP disclosed
EP-1178796-B1 ORAZAMIDE OROTATE FOR THE PREVENTION OF LIVER DAMAGE TACTICAL THERAPEUTICS INC (US) 2011-07-13 EP disclosed
CN-101516890-A Diaryl ketimine derivative BANYU PHARMA CO LTD (JP) 2009-08-26 CN disclosed
EP-1178796-A4 SALTS OF AMINOIMIDAZOLE CARBOXAMIDE USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASES SAVVIPHARM INC (US) 2004-07-14 EP disclosed
EP-1178796-A1 SALTS OF AMINOIMIDAZOLE CARBOXAMIDE USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASES Savvipharm Inc. (US) 2002-02-13 EP disclosed
US-6239137-B1 IN PRECANCEROUS AND CANCEROUS CELLS. SAVVIPHARM INC 2001-05-29 US disclosed
US-6184227-B1 ADMINISTERING A DETOXIFYING DOSAGE TO PATIENT TO PREVENT TISSUE DAMAGE BY ALCOHOLIC BEVERAGES, REACTIVE DRUG METABOLITES OR DIETARY TOXINS SAVVIPHARM INC. 2001-02-06 US disclosed
WO-2000078311-A1 SALTS OF AMINOIMIDAZOLE CARBOXAMIDE USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASES SAVVIPHARM INC. (US) 2000-12-28 WO disclosed